Boehringer Ingelheim GmbH Release: HIV-1 Patients with an Undetectable Viral Load Can Switch to VIRAMUNE(R) Regardless of Their CD4 Count

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim announced today that the European Commission has approved an update to the Summary of Product Characteristics (SmPC) for VIRAMUNE® (nevirapine) in the treatment of patients with HIV.